Jubilant HollisterStier to Invest USD 300 Million in US by FY28 to Double Sterile Injectable Capacity
NEW DELHI: Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharmova Ltd, plans to invest USD 300 million by FY28 in the United States to double its sterile injectable manufacturing capacity, the company announced on Friday.
According to Chris Preti, CEO of CDMO Sterile Injectables at Jubilant HollisterStier, the expansion plans have been accelerated by tariffs imposed under former US President Donald Trump, which have increased demand for domestic manufacturing.
The company has inaugurated a new sterile fill-and-finish line — its third — at its Spokane, Washington facility, established with an investment of USD 132 million. “This marks the first phase of our USD 300 million investment. Phase one adds 50% capacity, and the full expansion will be completed by FY28, doubling our total output,” Preti told PTI.
Currently, Jubilant HollisterStier produces around 50 million vials annually. Once both expansion phases are completed, production will increase to 100 million vials per year.
Preti noted that the investment is primarily driven by a demand-supply gap and customer demand for onshore manufacturing in the US. “The tariff situation has further amplified the need for US-based production. There’s a growing preference for onshore or nearshore manufacturing, including from Indian companies looking to diversify outside Asia,” he explained.
Citing a McKinsey study, Preti said there is a global shortfall of about 700 million sterile vials, with demand estimated at 6.8 billion units against a supply of 6.1 billion. Jubilant identified this gap two years ago and launched its capacity expansion to meet the increasing US demand, particularly after many manufacturers shifted to pre-filled syringes.
Following its success in manufacturing COVID-19 therapeutics, Jubilant HollisterStier received a USD 150 million grant from the US government, which helped kick-start the current USD 300 million expansion program.
Highlighting the project’s scale, Preti said, “Each unit equals about five patient doses — meaning our Spokane facility could soon supply nearly 350 million patient doses, covering almost the entire US population.”
Jubilant HollisterStier operates as a leading Contract Development and Manufacturing Organisation (CDMO), providing sterile fill-finish, lyophilization, and ophthalmic manufacturing services. The company has advanced facilities in Spokane, Washington, and Montreal, Quebec.
